{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:15:17Z","timestamp":1780539317161,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","award":["Funding Daiichi Sankyo provided financial support for medical writing services."],"award-info":[{"award-number":["Funding Daiichi Sankyo provided financial support for medical writing services."]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40261-019-00881-7","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T14:02:33Z","timestamp":1578405753000},"page":"227-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Practical Considerations for Treatment of Relapsed\/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-4091","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rodr\u00edguez-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Rodr\u00edguez-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"issue":"12","key":"881_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"8","key":"881_CR2","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1242\/dmm.015974","volume":"7","author":"CS Grove","year":"2014","unstructured":"Grove CS, Vassiliou GS. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech. 2014;7(8):941\u201351.","journal-title":"Dis Model Mech."},{"issue":"22","key":"881_CR3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"2","key":"881_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","volume":"109","author":"K Mrozek","year":"2007","unstructured":"Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109(2):431\u201348.","journal-title":"Blood"},{"issue":"9","key":"881_CR5","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/sj.leu.2402622","volume":"16","author":"N Boissel","year":"2002","unstructured":"Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. 2002;16(9):1699\u2013704.","journal-title":"Leukemia"},{"issue":"5","key":"881_CR6","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","volume":"111","author":"RE Gale","year":"2008","unstructured":"Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776\u201384.","journal-title":"Blood"},{"issue":"10","key":"881_CR7","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/leu.2014.90","volume":"28","author":"M Lazenby","year":"2014","unstructured":"Lazenby M, Gilkes AF, Marrin C, et al. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia. 2014;28(10):1953\u20139.","journal-title":"Leukemia"},{"issue":"12","key":"881_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079\u201389.","journal-title":"N Engl J Med"},{"issue":"6","key":"881_CR9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","volume":"34","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Kantarjian H, Faderl S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34(6):752\u20136.","journal-title":"Leuk Res"},{"issue":"18","key":"881_CR10","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1182\/blood-2010-05-283648","volume":"116","author":"SP Whitman","year":"2010","unstructured":"Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60\u00a0years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(18):3622\u20136.","journal-title":"Blood"},{"issue":"14","key":"881_CR11","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984\u201392.","journal-title":"Blood"},{"issue":"7","key":"881_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","volume":"19","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perl AE, Dohner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889\u2013903.","journal-title":"Lancet Oncol."},{"issue":"29","key":"881_CR13","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","volume":"31","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681\u20137.","journal-title":"J Clin Oncol"},{"key":"881_CR14","unstructured":"Daiichi Sankyo. Quizartinib hydrochloride tablets: Japanese prescribing information. 2019. http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/430574_4291060F1021_1_02#HDR_Warnings. Accessed 13 Nov 2019."},{"issue":"7","key":"881_CR15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol."},{"issue":"2","key":"881_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1182\/blood-2012-04-427039","volume":"121","author":"B Parkin","year":"2013","unstructured":"Parkin B, Ouillette P, Li Y, et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood. 2013;121(2):369\u201377.","journal-title":"Blood"},{"issue":"7382","key":"881_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506\u201310.","journal-title":"Nature"},{"issue":"36","key":"881_CR18","doi-asserted-by":"crossref","first-page":"58586","DOI":"10.18632\/oncotarget.10850","volume":"7","author":"X Zhang","year":"2016","unstructured":"Zhang X, Lv D, Zhang Y, et al. Clonal evolution of acute myeloid leukemia highlighted by latest genome sequencing studies. Oncotarget. 2016;7(36):58586\u201394.","journal-title":"Oncotarget."},{"issue":"4","key":"881_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/10428194.2017.1349907","volume":"59","author":"NJ Short","year":"2018","unstructured":"Short NJ, Kantarjian H, Ravandi F, et al. A phase I\/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018;59(4):813\u201320.","journal-title":"Leuk Lymphoma"},{"key":"881_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.exphem.2017.07.002","volume":"54","author":"C Hassan","year":"2017","unstructured":"Hassan C, Afshinnekoo E, Li S, et al. Genetic and epigenetic heterogeneity and the impact on cancer relapse. Exp Hematol. 2017;54:26\u201330.","journal-title":"Exp Hematol"},{"issue":"5","key":"881_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/bjh.14107","volume":"174","author":"JM Bergua","year":"2016","unstructured":"Bergua JM, Montesinos P, Martinez-Cuadron D, et al. A prognostic model for survival after salvage treatment with FLAG-Ida\u2009\u00b1\u2009gemtuzumab-ozogamicine in adult patients with refractory\/relapsed acute myeloid leukaemia. Br J Haematol. 2016;174(5):700\u201310.","journal-title":"Br J Haematol"},{"issue":"7","key":"881_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/sj.leu.2404246","volume":"20","author":"J Cloos","year":"2006","unstructured":"Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia. 2006;20(7):1217\u201320.","journal-title":"Leukemia"},{"issue":"7","key":"881_CR23","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2002-02-0420","volume":"100","author":"PD Kottaridis","year":"2002","unstructured":"Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100(7):2393\u20138.","journal-title":"Blood"},{"issue":"8","key":"881_CR24","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.5858\/2009-0292-OA.1","volume":"134","author":"SR McCormick","year":"2010","unstructured":"McCormick SR, McCormick MJ, Grutkoski PS, et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med. 2010;134(8):1143\u201351.","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"881_CR25","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1182\/blood-2002-01-0195","volume":"100","author":"LY Shih","year":"2002","unstructured":"Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387\u201392.","journal-title":"Blood"},{"issue":"4","key":"881_CR26","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-0835-03","volume":"10","author":"LY Shih","year":"2004","unstructured":"Shih LY, Huang CF, Wu JH, et al. Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin Cancer Res. 2004;10(4):1326\u201332.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"881_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3324\/haematol.10869","volume":"92","author":"U Bacher","year":"2007","unstructured":"Bacher U, Haferlach T, Kern W, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92(6):744\u201352.","journal-title":"Haematologica"},{"issue":"4","key":"881_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1309\/AJCP77ZFPUQGYGWY","volume":"144","author":"JM Ziai","year":"2015","unstructured":"Ziai JM, Siddon AJ. Pathology consultation on gene mutations in acute myeloid leukemia. Am J Clin Pathol. 2015;144(4):539\u201354.","journal-title":"Am J Clin Pathol"},{"issue":"14","key":"881_CR29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1161\/CIRCULATIONAHA.109.894725","volume":"122","author":"EK Heist","year":"2010","unstructured":"Heist EK, Ruskin JN. Drug-induced arrhythmia. Circulation. 2010;122(14):1426\u201335.","journal-title":"Circulation"},{"key":"881_CR30","unstructured":"A phase 3 open-label randomized study of quizartinib (AC220) monotherapy versus salvage chemotherapy in subjects with tyrosine kinase 3\u2014internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML) refractory to or relapsed after first-line treatment with or without hematopoietic stem cell transplantation (HSCT) consolidation [ClinicalTrials.gov record: NCT02039726] [database on the Internet]2018 [cited December 10 2018]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02039726."},{"issue":"9","key":"881_CR31","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1111\/bcp.14022","volume":"85","author":"J Li","year":"2019","unstructured":"Li J, Kankam M, Trone D, et al. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. Br J Clin Pharmacol. 2019;85(9):2108\u201317.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"881_CR32","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/00498254.2016.1217100","volume":"47","author":"M Sanga","year":"2017","unstructured":"Sanga M, James J, Marini J, et al. An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia. Xenobiotica. 2017;47(10):856\u201369.","journal-title":"Xenobiotica"},{"issue":"8","key":"881_CR33","doi-asserted-by":"publisher","first-page":"e71266","DOI":"10.1371\/journal.pone.0071266","volume":"8","author":"J Bhullar","year":"2013","unstructured":"Bhullar J, Natarajan K, Shukla S, et al. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS One. 2013;8(8):e71266.","journal-title":"PLoS One"},{"issue":"4","key":"881_CR34","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"881_CR35","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1592\/phco.30.8.842","volume":"30","author":"E Dodds-Ashley","year":"2010","unstructured":"Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy. 2010;30(8):842\u201354.","journal-title":"Pharmacotherapy."},{"issue":"9","key":"881_CR36","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00277-019-03744-5","volume":"98","author":"R Rodr\u00edguez-Veiga","year":"2019","unstructured":"Rodr\u00edguez-Veiga R, Montesinos P, Boluda B, et al. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Ann Hematol. 2019;98(9):2081\u20138.","journal-title":"Ann Hematol"},{"key":"881_CR37","doi-asserted-by":"crossref","unstructured":"Sandmaier BM, Khaled S, Oran B, et al. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2018;93(2):222\u201331.39. Fluconazole 50\u00a0mg Capsules. Summary of Product Characteristics. [database on the Internet] 2018 [cited 5 April 2019]. https:\/\/www.medicines.org.uk\/emc\/product\/6077\/smpc\/print.","DOI":"10.1002\/ajh.24959"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00881-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00881-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00881-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T12:33:01Z","timestamp":1613392381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00881-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00881-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737198640.793576183","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]},"assertion":[{"value":"7 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Daiichi Sankyo provided financial support for medical writing services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All patients gave written consent to take part in the study and the study was approved by the health authorities. The reference committee was the Ethical Committee of the Hospital Universitari i Polit\u00e8cnic La Fe, Valencia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"David Mart\u00ednez-Cuadr\u00f3n has acted in an advisory role for JazzPharma, Novartis, Pfizer, Teva and Daiichi Sankyo; has served on the Speakers\u2019 Bureau of Pfizer, Janssen, Amgen and Gilead; and has received travel grants from JazzPharma, Novartis, Pfizer and Amgen. Pau Montesinos has provided consultations or acted in an advisory role for JazzPharma, Novartis, AbbVie, Celgene, Shire, Takeda, Daiichi Sankyo, Pfizer, Tolero and Agios; has served on the Speakers\u2019 Bureau of Otsuka, Novartis, AbbVie, Celgene, Incyte, Daiichi Sankyo and Pfizer; has received research funding from Novartis, Janssen, Celgene, Daiichi Sankyo, Pfizer and Teva; and has received travel grants from Teva, Novartis, Celgene, Daiichi Sankyo and Amgen. Rebeca Rodr\u00edguez-Veiga has served on the Speakers\u2019 Bureau of Teva, Pfizer, Janssen and Novartis; and has received travel grants from Sanofi and Daiichi Sankyo. All other co-authors: nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}